UBS analyst Alex Kramm lowered the firm’s price target on CME Group (CME) to $280 from $285 and keeps a Neutral rating on the shares. The firm sees “no shortage of initiatives” at CME, but argues that the near-term volume picture “remains tough.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CME: